Physician profile
Matthew B Pride
NPI 1588627855
$4,975.20
in general payments reported to CMS, 2019-2025
13 companies · $78.95 in 2025
The $78.95 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $88.41 · 2023: $491 · 2024: $3,858 · 2025: $78.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,523 · Travel and Lodging: $1,339 · Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,522.96 |
| Travel and Lodging | $1,339.07 |
| Food and Beverage | $565.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,057.86 | 2023-2024 | Da Vinci Surgical System |
| Hologic Sales and Service, LLC | $350.73 | 2023-2025 | Acessa Provu System, Fluent Fluid Management System |
| Abbvie INC. | $163.92 | 2019-2020 | |
| Therapeuticsmd, INC. | $84.27 | 2019-2020 | |
| Pfizer INC. | $82.55 | 2019-2020 | |
| Covidien LP | $63.96 | 2019 | |
| Coopersurgical, INC. | $39.99 | 2019-2025 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $35.64 | 2019 | |
| Merck Sharp & Dohme LLC | $29.27 | 2019 | |
| Allergan, INC. | $19.82 | 2019 | |
| Roche Diagnostics Corporation | $17.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.48 | 2019 | |
| Sage Therapeutics, LLC | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.